cobas® eplex BCID-FP panel

Bringing the power of cobas eplex system syndromic panels together with Roche

IVD For in vitro diagnostic use.
cobas® eplex blood culture identification Fungal Pathogen (BCID-FP) panel
cobas eplex blood culture identification fungal pathogen (BCID-FP)

The cobas eplex BCID panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes.

The cobas eplex blood culture identification panels (BCID) broad coverage means that about 95% of currently identified bloodstream infections can be detected early, compared to other panels that detect significantly fewer sepsis-causing bacteria and fungi.

Infectious diseases, such as bloodstream infections that can lead to sepsis, respiratory infections and diarrhea are among the top causes of death worldwide.1,2

These and other infectious diseases can be considered syndromes (a group of symptoms that may not point to a specific causative agent) and may be difficult to diagnose using conventional diagnostic testing methods that look for a single or small number of disease-causing pathogens.

cobas eplex BCID panels for rapid, routine, blood culture identification
Explore the cobas eplex BCID panels benefits
Early identification helps improve patient outcomes


It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.3,4

The cobas eplex BCID panels aid you in the identification of bacterial and fungal organisms as well as antibiotic resistance genes in about 90 minutes of blood culture bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique solutions, like the cobas eplex system, can help to improve antimicrobial stewardship and optimize patient care.


The most comprehensive molecular blood culture panels

The cobas eplex BCID panels offer the broadest coverage5,6 of organisms and resistance markers that cause bloodstream infections (BSI) and can lead to sepsis, including anaerobes and multi-drug resistant organisms (MDRO), as well as common and emerging fungal pathogens (Table 1). The cobas eplex blood culture identification fungal pathogen panel  (BCID-FP) was the first FDA-cleared multiplex molecular panel to include Candida auris, a multi-drug resistant fungal organism that is increasing in prevalence around the world.7

The cobas eplex BCID panels detect more of the organisms that cause bloodstream infections than other multiplex panels.


% organism inclusivity

  5 US hospitals Clinical study Weighted average
Number of samples (n) 15,793 1,979 17,772
cobas® eplex BCID panels 94.1% 93.6% 94.0%
BioFire BCID 84.3% 86.6% 84.5%
BioFire BCID v2 86.8% 89.1% 87%
Luminex Verigene BC¹ 83.1% 83.0% 83.1%
Accelerate Pheno BC ID 78.1% 82.1% 78.5%
Accelerate Pheno BC AST 68.5% 74.4% 69.1%
Table 1: Blood culture panel target inclusivity based on prevalence of organisms that cause bloodstream infections in the United States – 3 clinical sample sets: a) Combined 5 US geographically diverse hospitals (n=15,793), b) GenMark’s prospective clinical trial database (n=1976 from 10 US clinical study sites)
Resistance genes inform rapid clinical decision making


The cobas eplex BCID panels include 4 gram-positive and 6 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials in the case of common contaminants or when a narrower antibiotic is more appropriate. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to have a high percent agreement with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.8


Rapidly rule-out blood culture contamination

As much as 15 to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics.9 The cobas eplex BCID panels are designed to allow you to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods. Common contaminants included on the cobas eplex BCID-GP panel but not on most competitor’s panels include:

  • Bacillus subtilis
  • Corynebacterium
  • Cutibacterium acnes
  • Micrococcus
  • Lactobacillus


Comprehensive coverage of pathogens and resistance genes
Fungal organisms

Candida albicans
Candida auris
Candida dubliniensis
Candida famata
Candida glabrata
Candida guilliermondii
Candida kefyr
Candida krusei
Candida lusitaniae
Candida parapsilosis
Candida tropicalis
Cryptococcus gattii
Cryptococcus neoformans


Access package inserts through your country’s Roche Diagnostics local website.

cobas® eplex system

cobas® eplex system

True sample-to-answer solution

The cobas eplex system integrates the entire process from order-to-report to better realize the patient and laboratory benefits of rapid, multiplex molecular diagnostics.


  1. Lozano R, et al., The Lancet 2012; 380: 2095–2128.
  2. Fact Sheet Sepsis. V2_Sepsis Fact Sheet. World Sepsis Day. Global Sepsis Alliance. Center for Sepsis Control & Care.
  3. IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics.
  4. Kumar, et al. (2006) Crit Care Med. 34 (6):1589-1596
  5. GenMark Blood Culture Identification - BCID- CE-IVD Package Insert
  6. BioFire Blood culture identification 2 (BCID2) panel [package insert RFIT-PRT-0841-02]. bioMerieux; Jun 2020.
  7. Tracking Candida auris: (accessed 7/6/2022)
  8. Pogue, JM, et al. (2018) Antimicrob Agents Chemother: 62(5):e02538-17
  9. Murray, P. et. al. (2012), Crit Care Med,Current Approaches to the Diagnosis of Bacterial and Fungal Bloodstream Infections for the ICU.


Detailed Specifications

Ordering Information

Compatible Instruments


    Technical Documents

    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later